Septerna, Inc. Share Price & Technical Analysis
SEPN · $28.36 (+1.58%)
Healthcare / Biotechnology
$28.36
+1.58%
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 n…
Price chart
Seasonality
May has 2 positive and 0 negative years (last 3 years shown)
19% return in May, 31% avg return in past 3 year May month.
10% return in 2026, 44% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -17% | 24% | -15% | -2% | 19% | – | – | – | – | – | – | – | 10% |
| 25 | -27% | -61% | -8% | 21% | 31% | 14% | 17% | -1% | 55% | 10% | 42% | -3% | 91% |
| 24 | – | – | – | – | – | – | – | – | – | -3% | 10% | -10% | -2% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.08B
P/E ratio
—
52W high
$32.63
52W low
$9.11
Volume
3,47,216
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Septerna, Inc. share price today?
- Septerna, Inc. (SEPN) last traded around $28.36 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SEPN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SEPN. Download the app for real-time alerts.
- How can I analyze Septerna, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.